Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Overview 6
Therapeutics Development 7
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Products under Development by Stage of Development 7
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Products under Development by Therapy Area 8
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Products under Development by Indication 9
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Products under Development by Companies 12
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Products under Development by Universities/Institutes 14
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Companies Involved in Therapeutics Development 21
Celgene Corporation 21
Eisai Co., Ltd. 22
OPKO Health, Inc. 23
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Drug Profiles 24
bentamapimod - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
CC-539 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CC-90001 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ER-358063 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecules to Activate JNK-1, JNK-2 and p38 MAP Kinase for Oncology - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
SR-3306 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Dormant Projects 31
Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Featured News & Press Releases 32
Oct 07, 2010: Richter Announces The Acquisition Of PregLem 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 18
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Celgene Corporation, H1 2016 21
Pipeline by Eisai Co., Ltd., H1 2016 22
Pipeline by OPKO Health, Inc., H1 2016 23
Dormant Projects, H1 2016 31

List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Mechanism of Actions, H1 2016 17
Number of Products by Stage and Mechanism of Actions, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 20